A few takeaways from Merck's (MRK +0.5%) presentation at Morgan Stanley's Healthcare Conference...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

A few takeaways from Merck's (MRK +0.5%) presentation at Morgan Stanley's Healthcare Conference today: Seeing solid H1 sales growth in all major businesses; Anticipates US/EU filing for Odanacatib in H113, Tredaptive U.S. filing should come in H113 as well; Januvia showing solid sales growth, YTD June sales were $2.8B; Singulair's U.S. patent expired in August, the company has seen an 87% decline in prescriptions within just a few weeks. (Audio)